KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - AccuredReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Twist Bioscience (TWST) Current Assets (2018 - 2026)

Twist Bioscience has reported Current Assets over the past 9 years, most recently at $323.4 million for Q1 2026.

  • Quarterly Current Assets fell 4.43% to $323.4 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $323.4 million through Mar 2026, down 4.43% year-over-year, with the annual reading at $333.0 million for FY2025, 3.98% down from the prior year.
  • Current Assets was $323.4 million for Q1 2026 at Twist Bioscience, up from $303.9 million in the prior quarter.
  • Over five years, Current Assets peaked at $664.4 million in Q1 2022 and troughed at $303.9 million in Q4 2025.
  • The 5-year median for Current Assets is $371.9 million (2024), against an average of $425.9 million.
  • Year-over-year, Current Assets surged 40.74% in 2022 and then fell 28.87% in 2023.
  • A 5-year view of Current Assets shows it stood at $541.9 million in 2022, then decreased by 27.98% to $390.2 million in 2023, then dropped by 11.51% to $345.3 million in 2024, then dropped by 12.0% to $303.9 million in 2025, then grew by 6.44% to $323.4 million in 2026.
  • Per Business Quant, the three most recent readings for TWST's Current Assets are $323.4 million (Q1 2026), $303.9 million (Q4 2025), and $333.0 million (Q3 2025).